All In Biotech

Drug Trial Radar · NCT07880886

Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean Fever

International, Multicenter, Open-label Clinical Study of Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Participants With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

May 2029

Study completion Apr 2030

Sponsor

Lead sponsor
R-PharmIndustry
Sponsor type
Industry
First posted
Oct 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 5 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to evaluate the main pharmacokinetic (PK) parameters, efficacy, and safety of goflikicept (GFC) in children and adolescents with colchicine-resistant or colchicine-intolerant familial Mediterranean fever (FMF).

Conditions

  • Familial Mediterranean Fever
  • FMF

Interventions

  • RPH-104Biological

    solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum serum concentration of goflikicept (Cmax (W16))Time frame: Visit 1 (Baseline) to Visit 10 (Week 16)
  2. Area under serum concentration-time curve for goflikicept (AUC(0-W16))Time frame: Visit 1 (Baseline) to Visit 10 (Week 16)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Federal State Budgetary Scientific Institution "V.A. Nasonova Research Institute of Rheumatology

    Moscow, Russia

  • State Budgetary Institution of Healthcare of the City of Moscow "Morozovskaya Children's City Clinical Hospital of the Moscow City Health Department" (GBUZ "Morozovskaya DGBK DZM")

    Moscow, Russia

  • LLC "Medical Technologies"

    Saint Petersburg, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.